Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP).
Thirty-two patients with metastatic breast cancer refractory to chemotherapy with combinations of cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone were treated with doxorubicin, mitolactol (dibromodulcitol), and mitomycin C. Two complete and 12 partial remissions were observed for a response rate of 435. When only those patients who were considered evaluable were included (the 26 patients who had received more than one course of therapy), the response rate was 53%. Hematologic toxicity was moderate-to-severe. Responses were seen in visceral, osseous, and soft tissue tumor sites. The median time to the development of disease progression was 30 weeks for responding patients. The median survival of responders has not yet been reached at 48 weeks.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D008936:Mitolactol / Q000008:administration & dosage* / Q000009:adverse effects; D008937:Mitomycins / Q000008:administration & dosage* / Q000009:adverse effects; D009362:Neoplasm Metastasis; D011379:Prognosis
D000970:Antineoplastic Agents; D008937:Mitomycins; D004317:Doxorubicin; D008936:Mitolactol